Atrial arrhythmias associated with anti-tumor drugs in patients with malignant tumors and type 2 diabetes mellitus
T2DM significantly amplifies atrial arrhythmia risk in cancer patients receiving antitumor drugs, particularly anthracyclines. Age, ischemic heart disease, and biomarker trends are critical risk indicators. Proactive ECG and biomarker monitoring, coupled with cardio-oncology collaboration, are essential for mitigating arrhythmia-related morbidity.
Authors
- Yili Ren
- Beibei Zhang (ORCID: https://orcid.org/0000-0002-7022-5403)
- Lei Zhang (ORCID: https://orcid.org/0000-0002-2227-0613)
- Chenkai Xu (ORCID: https://orcid.org/0009-0003-6386-4121)
Institutions
- Shaoxing University (CN)
- Zhejiang Hospital (CN)
- Shaoxing People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.3389/fonc.2025.1598921
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 1.39